Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Misses on EPS, Stock Down 3.9%

The earnings report indicates that Arrowhead Pharmaceuticals faced significant challenges this quarter, particularly reflected in their EPS miss. The stock reacted negatively, dropping 3.9%, likely due to investor concerns about the company's performance and lack of guidance. Without clear direction from management, uncertainty may linger among investors.